Jody C. Chuang

发表

Peter A. Jones, Jody C. Chuang, JODY C. CHUANG, 2007, Pediatric Research.

Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells.

Peter A. Jones, G. Coetzee, J. Friedman, 2006, Cancer cell.

Molecular profiling reveals synaptic release machinery in Merkel cells.

Jonathon Howard, Ellen A Lumpkin, J. Howard, 2004, Proceedings of the National Academy of Sciences of the United States of America.

ERBB2‐Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies

H. Stehr, J. Neal, H. Wakelee, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy.

M. Socinski, H. Wakelee, C. Langer, 2018, Journal of thoracic disease.

Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine

Peter A. Jones, A. Yang, G. Liang, 2005, Molecular Cancer Therapeutics.

Preferential response of cancer cells to zebularine.

Gangning Liang, Peter A. Jones, D. Weisenberger, 2004, Cancer cell.

Long-term Epigenetic Therapy with Oral Zebularine Has Minimal Side Effects and Prevents Intestinal Tumors in Mice

Peter A. Jones, P. Laird, T. Long, 2008, Cancer Prevention Research.

Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions

H. Wakelee, Jody C. Chuang, A. Salahudeen, 2016, Expert opinion on pharmacotherapy.

The persistent promise of combining HGF/MET and EGFR inhibition in non‐small cell lung cancer

J. Neal, Jody C. Chuang, 2017, Cancer.

Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.

J. Neal, H. Wakelee, Jody C. Chuang, 2015, Lung cancer.

Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS

G. Berry, H. Wakelee, Jody C. Chuang, 2017, Current Treatment Options in Oncology.

Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer.

H. Wakelee, Jody C. Chuang, Ying-ying Liang, 2017, Hematology/oncology clinics of North America.

S110, a 5-Aza-2′-Deoxycytidine–Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor In vivo and Can Reduce Tumor Growth

Peter A. Jones, D. Bearss, Jody C. Chuang, 2010, Molecular Cancer Therapeutics.

Molecular Cancer Therapeutics S 110 , a 5-Aza-2 ′-Deoxycytidine – Containing Dinucleotide , Is an Effective DNA Methylation Inhibitor In vivo and Can Reduce Tumor Growth

Peter A. Jones, D. Bearss, Jody C. Chuang, 2010 .

Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells.

J. Friedman, G. Liang, Jody C. Chuang, 2009, Biochemical and biophysical research communications.

Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers.

J. Neal, Jody C. Chuang, 2015, Translational lung cancer research.

Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy.

J. Shrager, J. Neal, H. Wakelee, 2016, Clinical therapeutics.

Activin Signaling and Its Role in Regulation of Cell Proliferation, Apoptosis, and Carcinogenesis

Ye Guang Chen, Jody C. Chuang, C. Chang, 2006, Experimental biology and medicine.

The persistent promise of combining HGF/MET and EGFR inhibition in non‐small cell lung cancer

J. Neal, Jody C. Chuang, 2017, Cancer.